Neumora Therapeutics, Inc.
NMRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001885522
In the last 90 days, Neumora Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 113 institutions reported holding it in 13F filings for Q2 2026, worth $129.2M in total; no superinvestor holds it.
Holders of 5% or more of NMRA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Neumora Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| ARCH Venture Fund XII, L.P. | 13D/A | 18.70%34.0M shares | −2.00 ppfrom 20.70% | Oct 2, 20235 filings | Apr 1, 2026 | SEC |
| Berns Paul L | 13G/A | 5.10%8.23M shares | – | Feb 14, 20242 filings | Feb 13, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
18 Schedule 13D and 13G filings on Neumora Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 15, 20265:16 PM ET | K2 HealthVentures Equity Trust LLCand 2 others | 13G/A | 3.10%5.79M shares | −1.91 ppfrom 5.01%Below 5% | Mar 31, 2026 | SEC |
| May 4, 20262:08 PM ET | Invus Global Management, LLCand 7 others | 13G/A | 4.70%8.50M shares | −0.70 ppfrom 5.40%Below 5% | Mar 31, 2026 | SEC |
| Apr 1, 20264:10 PM ET | ARCH Venture Fund XII, L.P.and 17 others | 13D/A | 18.70%34.0M shares | −2.00 ppfrom 20.70% | Mar 30, 2026 | SEC |
| Feb 19, 20264:37 PM ET | Invus Global Management, LLCand 7 others | 13G | 5.40%9.00M shares | New | Feb 13, 2026 | SEC |
| Feb 17, 20264:41 PM ET | K2 HealthVentures Equity Trust LLCand 2 others | 13G/A | 5.01%9.00M shares | −1.59 ppfrom 6.60% | Dec 31, 2025 | SEC |
| Oct 29, 20257:07 PM ET | ARCH Venture Fund XII, L.P.and 17 others | 13D/A | 20.70%34.0M shares | – | Oct 27, 2025 | SEC |
| Aug 11, 20254:55 PM ET | K2 HealthVentures Equity Trust LLCand 2 others | 13G | 6.60%11.4M shares | New | May 9, 2025 | SEC |
| May 12, 202510:36 AM ET | FMR LLCand 1 other | 13G/A | 2.20%3.50M shares | −3.20 ppfrom 5.40%Below 5% | Mar 31, 2025 | SEC |
| Feb 13, 20254:30 PM ET | Berns Paul L | 13G/A | 5.10%8.23M shares | – | Dec 31, 2024 | SEC |
| Nov 22, 2024 | ARCH Venture Fund XII, L.P. | 13D/AOld format | – | – | – | SEC |
| Nov 12, 2024 | Softbank Group Corp | 13GOld format | – | – | – | SEC |
| Jul 8, 20244:15 PM ET | FMR LLCand 1 other | 13G | 5.40%8.62M shares | 0.00 ppfrom 5.40% | Jun 28, 2024 | SEC |
| Jul 8, 20241:07 PM ET | FMR LLCand 1 other | 13G | 5.40%8.62M shares | New | Jun 28, 2024 | SEC |
| Feb 14, 2024 | Berns Paul L | 13GOld format | – | New | – | SEC |
| Feb 13, 2024 | Softbank Group Corp | 13GOld format | – | New | – | SEC |
| Dec 15, 2023 | ARCH Venture Fund XII, L.P. | 13D/AOld format | – | – | – | SEC |
| Oct 2, 2023 | ARCH Venture Fund XII, L.P. | 13DOld format | – | New | – | SEC |
| Sep 27, 20237:30 AM ET | Amgen Inc | 13DOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Neumora Therapeutics, Inc. shares.
No Form 144 notices for Neumora Therapeutics, Inc. are on file.